Recent controlled clinical trials have confirmed the use-fulness of aerosolized tobramycin in cystic fibrosis and have emphasized the importance of ensuring adequate lung deliv-ery of inhaled antimicrobials. For purulent tracheobronchitis associated with prolonged mechanical ventilation it has re-cently been established that it is possible to deliver substantial and measurable doses of medications to the airway via aero-solization, but controlled studies are needed to determine the efficacy and safety of inhaled antibiotic therapy in this set-ting. However, prophylactic aerosolized antibiotic therapy in an intensive care unit setting may be counterproductive. Aero-solized pentamidine continues to provide prophylaxis against PCP in a substantial minority of subjects with human immu-nodeficiency virus infection who are intolerant of oral agents. The effectiveness of aerosolized amphotericin B as prophy-laxis against aspergillosis in neutropenic patients needs to be evaluated in a large clinical trial. Zanamivir, an inhibitor of neuraminidase, delivered via inhalation, shows promise in the treatment of uncomplicated influenza infection, but more data are needed on its effectiveness and safety in patients with preexisting respiratory disease. The development of new chemical entities, more efficient delivery systems, and more precise measurement of dose-response and regional pulmo-nary drug distribution of inhaled antimicrobials suggest that this somewhat neglected topic in therapeutics may be about to receive an increased degree of attention.
TosoC, WilliamsDM, NoonePG. Inhaled antibiotics in cystic fi-brosis: a review. Ann Pharmacother1996;30(7-8):840–850.
2.
PinesA, RaafatH, PlucinskiK.Gentamicin and colistin in chronic purulent bronchial infections. Br Med J1967;2(551):543–545.
3.
BrysonV, SansomeE, LaskinS.Aerosolization of penicillin solu-tions. Science1944;100:33–35.
4.
RamseyBW, DorkinHL, EisenbergJD, GibsonRL, HarwoodIR, KravitzRM, et al. Efficacy of aerosolized tobramycin in patients with cystic fibrosis. N Engl J Med1993;328(24):1740–1746.
5.
RamseyBW, PepeMS, QuanJM, OttoKL, MontgomeryAB, Wil-liams-WarrenJ, et al. Intermittent administration of inhaled tobra-mycin in patients with cystic fibrosis Cystic Fibrosis Inhaled Tobra-mycin Study Group. N Engl J Med1999;340(1):23–30.
6.
SmaldoneGC, O'RiordanTG. Aerosol deposition and clearance. In: WagnerHN, editor. Principles of nuclear medicine, 2nd ed. Philadelphia: WB Saunders; 1995: 895–905.
7.
O'RiordanTG, FarisM.Inhaled antimicrobial therapy. Respir Care Clin N Am1999;5(4):617–631.
8.
LeoungGS, FeigalDWJr, MontgomeryAB, CorkeryK, WardlawL, AdamsM, et al. Aerosolized pentamidine for prophylaxis against Pneumocystis carinii pneumonia: the San Francisco community pro-phylaxis trial. New Engl J Med1990;323(12):769–775.
9.
Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections. The MIST (Man-agement of Influenza in the Southern Hemisphere Trialists) Study Group. Lancet1998;352(9144):1877–1881.
10.
SmaldoneGC. Drug delivery via aerosol systems: concept of "aero-sol inhaled". J Aerosol Med1991;4(3):229–235.
11.
BennettWD. Aerosolized drug delivery: fractional deposition of inhaled particles. J Aerosol Med1991;4(13):223–229.
12.
HillerFC. Health implications of hygroscopic particle growth in the human respiratory tract. J Aerosol Med1991;4:1–23.
13.
DavisSS, HardyJG, NewmanSP, WildingIR. Gamma scintigraphy in the evaluation of pharmaceutical dosage forms (review). Eur J Nucl Med1992;19(11):971–986.
14.
SmaldoneGC, FuhrerJ, SteigbigelRT, McPeckM.Factors deter-mining pulmonary deposition of aerosolized pentamidine in patients with human immunodeficiency virus infection. Am Rev Respir Dis1991;143(4 Pt 1):727–737.
15.
IlowiteJS, GorvoyJD, SmaldoneGC. Quantitative deposition of aerosolized gentamicin in cystic fibrosis. Am Rev Respir Dis1987;136(6):1445–1449.
16.
SmaldoneGC, VinciguerraC, MorraL.Urine pentamidine as an indicator of lung pentamidine in patients receiving aerosol therapy. Chest1991;100(5):1219–1223.
17.
Le ConteP, PotelG, PeltierP, HoreauD, CaillonJ, JuvinME, et al. Lung distribution and pharmacokinetics of aerosolized tobramycin. Am Rev Respir Dis1993;147(5):1279–1282.
18.
MendelmanPM, SmithAL, LevyJ, WeberA, RamseyB, DavisRL. Aminoglycoside penetration, inactivation, and efficacy in cystic fi-brosis sputum. Am Rev Respir Dis1985;132(4):761–765.
19.
HodsonME, PenkethARL, BattenJC. Aerosol carbenicillin and gentamicin treatment of Pseudomonas aeruginosa infection in pa-tients with cystic fibrosis. Lancet1981;2(8256):1137–1139.
20.
MacLuskyIB, GoldR, CoreyM, LevisonH.Long-term effects of inhaled tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa. Pediatr Pulmonol1989;7(1):42–48.
ValeriusNH, KochC, HoibyN.Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment. Lancet1991;338(8769):725–726.
23.
NolanG, MoivorP, LevisonH, FlemingPC, CoreyM, GoldR.Antibiotics prophylaxis in cystic fibrosis: inhaled cephaloradine as an adjunct to oral cloxacillin. J Pediatr1982;101(4):626–630.
24.
SchaadUB, WedgewoodK, KruckoJ, SuterS, KraemerR.Efficacy of inhaled amikacin as adjunct to intravenous combination therapy (cefta-zidime and amikacin) in cystic fibrosis. J Pediatr1987;111(4):599–605.
25.
StephensD, GareyN, IslesA, LevisonH, GoldR.Efficacy of inhaled tobramycin in the treatment of pulmonary exacerbations in children with cystic fibrosis. Pediatr Infect Dis1983;2(3):209–211.
26.
FeeleyTW, Du MoulinGC, Hedley-WhyteJ, BushnellLS, GilbertJP, FeingoldDS. Aerosol polymyxin and pneumonia in seriously ill patients. New Engl J Med1975;293(10):471–475.
27.
PalmerLB, SmaldoneGC, SimonSR, O'RiordanTG, CucciaA.Aerosolized antibiotics in mechanically ventilated patients: delivery and response. Crit Care Med1999;26(1):31–39.
28.
O'RiordanTG, PalmerLB, SmaldoneGC. Aerosol deposition in mechanically ventilated patients: optimizing nebulizer delivery. Am J Respir Crit Care Med1994;149(1):214–219.
29.
MontgomeryAB, DebsRJ, LuceJM, CorkeryKJ, TurnerJ, BrunetteEN, LinET, HopewellPC. Aerosolised pentamidine as sole therapy for Pneumocystis carinii pneumonia in patients with acquired im-munodeficiency syndrome. Lancet1987;2(8557):480–483.
30.
BozzetteSA, FinkelsteinDM, SpectorSA, FrameP, PowderlyWG, HeW, et al. A randomized trial of three antipneumocystis agents in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials. New Engl J Med1995;332(11):693–699.
31.
Jules-ElyseeK, StoverDE, ZamanMB, BernardEM, WhiteDA. Aerosolized pentamidine: effect on diagnosis and presentation of Pneumocystis carinii pneumonia. Ann Intern Med1990;112(10):750–757.
32.
O'RiordanTG, SmaldoneG.Exposure of health-care workers to aerosolized pentamidine. Chest1992;101(16):1494–1499.
33.
McIvorRA, Lee-PackLR, ChanCK. Occupational exposure and pulmonary function in health care workers in an aerosol pentamidine clinic. Chest1994;106(3):980–981.
34.
CrossCE. Amphotericin B aerosol for transiently immunocompro-mised hosts: reasonably safe, but does it matter?Chest1995;108(3):599–601.
35.
HertensteinB, KernWV, SchmeiserT, StefanicM, BunjesD, WiesnethM, et al. Low incidence of invasive fungal infections after bone marrow transplantation in patients receiving amphotercin B inhalations during neutropenia. Ann Hematol1994;68(1):21–26.
36.
BeyerJ, BarzenG, RisseG, WeyerC, MiksitsK, DullenkopfK, et al. Aerosol amphotericin B for prevention of invasive pulmonary aspergillosis. Antimicrob Agents Chemother1993;37(6):1367–1369.
37.
ReichenspurnerH, GambergP, NitschkeM, ValentineH, HuntS, OyerPE, et al. Significant reduction in the number of fungal infec-tions after lung, heart-lung, and heart transplantation using aerosol-ized amphotercin B prophylaxis. Transplantation Proceedings1997;29(1-2):627–628.
38.
TsourounisC, GuglielmoBJ. Aerosolized amphotercin B in prophy-laxis of pulmonary aspergillosis. Ann Pharmacother1996;30(10):1175–1176.
39.
McEvoyGK, editor. American Hospital Formulary Service. Drug Information 1998; Ribavirin. American Society of Health System Pharmacists. Bethesda; 1998: 506–51.
40.
OttoliniMG, HemmingVG. Prevention and treatment recommenda-tions for respiratory syncytial virus infection: background and clinical experience 40 years after discovery. Drugs1997;54:867–884.
41.
SmithDW, FrankelLR, MathersLH, et al. A controlled trial of aerosolized ribavirin in infants receiving mechanical ventilation for severe respiratory syncytial virus infection. N Engl J Med1991;325(1):24–29.
42.
MeertKI, SarnaikAP, GelminiMJ, Lieh-LaiMW. Aerosolized riba-virin in mechanically ventilated children with respiratory syncytial virus lower respiratory disease: a prospective, double-blind, random-ized trial. Crit Care Med1994;22(4):566–572.
43.
GilbertBE, KnightV.Ribavirin aerosol as the treatment for influenza. Drugs Today1990;26:195–205.
44.
SullivanKM. Health impact of influenza in the United States. Phar-maco Eco1996;9:(Suppl 3):26–33.
45.
HaydenFG, OsterhausAD, TreanorJJ, FlemingDM, AokiFY, NicholsonKG, et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group. N Engl J Med1997;337(13):874–880.
